Literature DB >> 19744597

Nephrogenic systemic fibrosis: history and epidemiology.

Henrik S Thomsen1.   

Abstract

Nephrogenic systemic fibrosis (NSF) is a new disease; the first case was diagnosed in 1997. It took 9 years before an association between NSF and gadolinium-based contrast agents (Gd-CAs) was identified. Gadolinium has several advantages for use in relation to enhanced MRI, but it is also a toxic heavy metal. For nearly 20 years, it was believed that Gd-CAs were safe, and they were used liberally. The prevalence of NSF cases varies between the various Gd-CAs, and adequate documentation of NSF cases after exposure to extracellular Gd-CAs remains a problem. All evidence points toward the fact that the real number of patients who have NSF has not been accurately totaled; the disease seems to be underdiagnosed for various reasons.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19744597     DOI: 10.1016/j.rcl.2009.05.003

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN: 0033-8389            Impact factor:   2.303


  23 in total

1.  Dynamic contrast-enhanced MRI promotes early detection of toxin-induced acute kidney injury.

Authors:  Jamie R Privratsky; Nian Wang; Yi Qi; Jiafa Ren; Benjamin T Morris; John C Hunting; G Allan Johnson; Steven D Crowley
Journal:  Am J Physiol Renal Physiol       Date:  2018-12-05

Review 2.  Revisiting an old friend: manganese-based MRI contrast agents.

Authors:  Dipanjan Pan; Shelton D Caruthers; Angana Senpan; Ann H Schmieder; Samuel A Wickline; Gregory M Lanza
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2010-09-21

3.  Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report.

Authors:  B J Edwards; A E Laumann; B Nardone; F H Miller; J Restaino; D W Raisch; J M McKoy; J A Hammel; K Bhatt; K Bauer; A T Samaras; M J Fisher; C Bull; E Saddleton; S M Belknap; H S Thomsen; E Kanal; S E Cowper; A K Abu Alfa; D P West
Journal:  Br J Radiol       Date:  2014-10       Impact factor: 3.039

4.  Contrast agents for MRI: 30+ years and where are we going?

Authors:  Valérie C Pierre; Matthew J Allen; Peter Caravan
Journal:  J Biol Inorg Chem       Date:  2014-01-11       Impact factor: 3.358

5.  Surveillance of hepatocellular carcinoma by medical imaging.

Authors:  Christoph F Dietrich; Andreas Teufel; Claude B Sirlin; Yi Dong
Journal:  Quant Imaging Med Surg       Date:  2019-11

Review 6.  Role of multimodality imaging in ischemic and non-ischemic cardiomyopathy.

Authors:  Karthikeyan Ananthasubramaniam; Ritesh Dhar; João L Cavalcante
Journal:  Heart Fail Rev       Date:  2011-07       Impact factor: 4.214

7.  Comparison of the sensitivity of a pre-MRI questionnaire and point of care eGFR testing for detection of impaired renal function.

Authors:  Philip Chang; Elise Saddleton; Anne E Laumann; Brenda Schmitz; Dennis P West; Steven M Belknap; Sudharshan Parthasarathy; Beatrice J Edwards; June M McKoy; Frank H Miller
Journal:  Acad Radiol       Date:  2012-07-24       Impact factor: 3.173

8.  Summary of Imaging in 2020: Visualizing the Future of Healthcare with MR Imaging.

Authors:  Brooke A Corbin; Alyssa C Pollard; Matthew J Allen; Mark D Pagel
Journal:  Mol Imaging Biol       Date:  2019-04       Impact factor: 3.488

Review 9.  Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines.

Authors:  Henrik S Thomsen; Sameh K Morcos; Torsten Almén; Marie-France Bellin; Michele Bertolotto; Georg Bongartz; Olivier Clement; Peter Leander; Gertraud Heinz-Peer; Peter Reimer; Fulvio Stacul; Aart van der Molen; Judith A W Webb
Journal:  Eur Radiol       Date:  2012-08-04       Impact factor: 5.315

10.  IVIM perfusion fraction is prognostic for survival in brain glioma.

Authors:  Christian Federau; Milena Cerny; Marion Roux; Pascal J Mosimann; Philippe Maeder; Reto Meuli; Max Wintermark
Journal:  Clin Neuroradiol       Date:  2016-04-26       Impact factor: 3.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.